Skip to content
Last sale
Nov 12, 2026 · -0.29%
Market cap
$124.30B
115.46M shares
Filings
1,060
$110.96B
Q2 2027+12.4% FY26 yoy
$1.22B
Q2 2027+44.5% FY26 yoy
$1.60B
Q2 2027+40.5% FY26 yoy
$2.67B
Q2 2027derived+3.1% FY26 yoy
$10.44
Q2 2027+49.2% FY26 yoy
$6.53B
Q2 2027−30.2% FY26 yoy
$124.30B
26.4×
0.3×
—
5.72%
0.32%

Twelve months to Sep 30, 2026 · derived

Price

$1,076.63+25.76%+$220.53past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$403.43BFY 2026
$403.43B0FY 2015FY 2020FY 2026
PeriodEndedValueKindSource trail
FY 20262026-03-31$403,430,000,000reported
FY 20252025-03-31$359,051,000,000reported
FY 20242024-03-31$308,951,000,000reported
FY 20232023-03-31$276,711,000,000reported
FY 20222022-03-31$263,966,000,000reported
FY 20212021-03-31$238,228,000,000reported
FY 20202020-03-31$231,051,000,000reported
FY 20192019-03-31$214,319,000,000reported
FY 20182018-03-31$208,357,000,000reported
FY 20172017-03-31$198,533,000,000reported
FY 20162016-03-31$190,884,000,000reported
FY 20152015-03-31$179,045,000,000reported

Capital returns

Dividends and buybacks · FY2017 to FY2026
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2026$381.00M$4.75B$5.13B$3.17120.20M sh−3.9%89.7%
FY2025$345.00M$3.15B$3.49B$2.75125.11M sh−3.7%62.9%
FY2024$314.00M$3.03B$3.34B$2.40129.99M sh−4.1%86.0%
FY2023$292.00M$3.64B$3.93B$2.09135.60M sh−6.7%82.4%
FY2022$277.00M$3.52B$3.79B$1.83145.37M sh−8.1%93.7%

Segments

Segments
Revenue by Segments, FY2019 to FY2026FY2019Medical-Surgical Solutions · FY2019 · $7.62BPrescription Technology Solutions · FY2019 · $2.49BInternational · FY2019 · $38.02BU.S. Pharmaceutical · FY2019 · $166.19BFY2020Medical-Surgical Solutions · FY2020 · $8.31BPrescription Technology Solutions · FY2020 · $2.71BInternational · FY2020 · $38.34BU.S. Pharmaceutical · FY2020 · $181.70BFY2021Medical-Surgical Solutions · FY2021 · $10.10BPrescription Technology Solutions · FY2021 · $2.89BInternational · FY2021 · $35.97BU.S. Pharmaceutical · FY2021 · $189.27BFY2022Medical-Surgical Solutions · FY2022 · $11.61BPrescription Technology Solutions · FY2022 · $3.86BInternational · FY2022 · $36.35BU.S. Pharmaceutical · FY2022 · $212.15BFY2023Medical-Surgical Solutions · FY2023 · $11.11BPrescription Technology Solutions · FY2023 · $4.39BInternational · FY2023 · $20.60BU.S. Pharmaceutical · FY2023 · $240.62BFY2024North American Pharmaceutical · FY2024 · $261.37BOncology & Multispecialty · FY2024 · $30.49BMedical-Surgical Solutions · FY2024 · $11.31BPrescription Technology Solutions · FY2024 · $4.77BInternational · FY2024 · $14.13BU.S. Pharmaceutical · FY2024 · $278.74BFY2025North American Pharmaceutical · FY2025 · $304.51BOncology & Multispecialty · FY2025 · $36.86BMedical-Surgical Solutions · FY2025 · $11.38BPrescription Technology Solutions · FY2025 · $5.22BInternational · FY2025 · $14.72BU.S. Pharmaceutical · FY2025 · $327.72BFY2026North American Pharmaceutical · FY2026 · $336.65BOncology & Multispecialty · FY2026 · $48.42BMedical-Surgical Solutions · FY2026 · $11.51BPrescription Technology Solutions · FY2026 · $5.81B
LineFY2026ShareChange
North American Pharmaceutical$336.65B83%+10.6%
Oncology & Multispecialty$48.42B12%+31.4%
Medical-Surgical Solutions$11.51B2.9%+1.1%
Prescription Technology Solutions$5.81B1.4%+11.3%
International———
U.S. Pharmaceutical———
Total$403.43B

From the 10-K filed May 8, 2026MCK

Wholesale drugs, proprietaries & druggists’ sundries

McKesson Corp is the largest of the 11 covered companies the SEC files under this code, by revenue. SIC 5122

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

McKesson Corp · CIK 927653 · Engraved from SEC EDGAR